prodigiosene-estrone conjugate 3c

Prodigiosene-estrone conjugate 3c is a research-stage small molecule hybrid compound consisting of a synthetic prodigiosene (a prodigiosin analogue) covalently conjugated to estrone via an 8-carbon ester linker. Developed by Alison Thompson's group at Dalhousie University, this first-generation conjugate was designed to target estrogen receptor-positive (ER+) breast cancer cells with greater selectivity than prodigiosin alone. The estrone moiety acts as a targeting ligand to direct the cytotoxic tripyrrolic prodigiosene scaffold to the estrogen receptor (ER). In biological testing against the MCF-7 breast cancer cell line, compound 3c exhibited modest antiproliferative activity but performed relatively poorly compared to shorter-chain analogues (3a and 3b), likely due to the high sensitivity of its ester linkage to hydrolysis, which limits its stability.

Other names

compound 3ccompound3ccompound-3cprodigiosene-estrone conjugate 3c